Bergenbio ASA
OSE:BGBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bergenbio ASA
OSE:BGBIO
|
NO |
|
B
|
Balco Group AB
LSE:0RUW
|
SE |
|
Himatsingka Seide Ltd
NSE:HIMATSEIDE
|
IN |
|
M
|
Matrix IT Ltd
TASE:MTRX
|
IL |
|
Y.A.C. Holdings Co Ltd
TSE:6298
|
JP |
|
InPost SA
AEX:INPST
|
LU |
|
Avic Shenyang Aircraft Co Ltd
SSE:600760
|
CN |
|
M
|
Mitrajaya Holdings Bhd
KLSE:MHB
|
MY |
|
Super Crop Safe Ltd
BSE:530883
|
IN |
|
Lenovo Group Ltd
HKEX:992
|
CN |
|
Insignia Financial Ltd
ASX:IFL
|
AU |
|
S
|
Shandong Weigao Blood Purification Products Co Ltd
SSE:603014
|
CN |
|
China Silver Group Ltd
HKEX:815
|
CN |
|
D
|
Douglas Elliman Inc
NYSE:DOUG
|
US |
|
Feitian Technologies Co Ltd
SZSE:300386
|
CN |
|
D
|
Dar Global PLC
LSE:DAR
|
UK |
|
Kimura Co Ltd
TSE:7461
|
JP |
|
Seri Industrial SpA
MIL:SERI
|
IT |
|
P
|
PetroVietnam Drilling & Well Service Corp
VN:PVD
|
VN |
Bergenbio ASA
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
